Abstract
Statin is now recommended in secondary prevention after stroke or transient ischemic attacks to reduce the risk of a new stroke or major cardiovascular events. However, some issues about the extent of the benefit in some stroke patients and the risk of cerebral hemorrhage remain debated. This review shows that statins are significantly effective in decreasing the risk of further strokes despite an increase in the risk of brain hemorrhage. A significant benefit was observed in men and women, in aged patients and possibly to a greater extent in patients with carotid artery stenosis. Intensive statin therapy lowering the LDL-cholesterol beyond the cut-off value of 1.8 mmol/L (70 mg/dl) seems to be more effective than less intensive treatment and without an increased risk of side effects. Overall, statins are well tolerated. Further prospective studies should clarify whether the effect is of the same magnitude in small vessel disease and how to select the patients to reduce the risk of cerebral hemorrhage.
Keywords: Carotid stenosis, cerebral hemorrhage, cholesterol, risk, statins, stroke, therapy, treatment.
Current Vascular Pharmacology
Title:Risk and Benefit of Statins in Stroke Secondary Prevention
Volume: 11 Issue: 6
Author(s): Patrice Laloux
Affiliation:
Keywords: Carotid stenosis, cerebral hemorrhage, cholesterol, risk, statins, stroke, therapy, treatment.
Abstract: Statin is now recommended in secondary prevention after stroke or transient ischemic attacks to reduce the risk of a new stroke or major cardiovascular events. However, some issues about the extent of the benefit in some stroke patients and the risk of cerebral hemorrhage remain debated. This review shows that statins are significantly effective in decreasing the risk of further strokes despite an increase in the risk of brain hemorrhage. A significant benefit was observed in men and women, in aged patients and possibly to a greater extent in patients with carotid artery stenosis. Intensive statin therapy lowering the LDL-cholesterol beyond the cut-off value of 1.8 mmol/L (70 mg/dl) seems to be more effective than less intensive treatment and without an increased risk of side effects. Overall, statins are well tolerated. Further prospective studies should clarify whether the effect is of the same magnitude in small vessel disease and how to select the patients to reduce the risk of cerebral hemorrhage.
Export Options
About this article
Cite this article as:
Laloux Patrice, Risk and Benefit of Statins in Stroke Secondary Prevention, Current Vascular Pharmacology 2013; 11 (6) . https://dx.doi.org/10.2174/157016111106140128113121
DOI https://dx.doi.org/10.2174/157016111106140128113121 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelial Progenitor Cells and In-stent Restenosis
Current Stem Cell Research & Therapy Editorial: Time for Earlier and More Intensive Preventive Therapy
Current Vascular Pharmacology Neutrophil F-actin Dynamics in Familial Mediterranean Fever: The Unequal Effect of Colchicine on Activated Neutrophils
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Acute Physical Stress Increases Serum Levels of Specific microRNAs
MicroRNA The Effect of Anti-B-cell Therapy on the Development of Atherosclerosis in Patients with Rheumatoid Arthritis
Current Pharmaceutical Design Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design Postconditioning: A New Paradigm for Myocardial Protection?
Current Cardiology Reviews Marine n-3 Fatty Acids for Cardiovascular Risk Reduction and Disease Control in Rheumatoid Arthritis: “Kill Two Birds with One Stone”?
Current Pharmaceutical Design Role of Polymorphisms in Factor V (FV Leiden), Prothrombin, Plasminogen Activator Inhibitor Type-1 (PAI-1), Methylenetetrahydrofolate Reductase (MTHFR) and Cystathionine β-Synthase (CBS) Genes as Risk Factors for Thrombophilias
Mini-Reviews in Medicinal Chemistry Systematic Review of Public Education and Policy for Stroke Prevention
Current Drug Targets Regulation of Angiotensin II Receptor Expression
Current Pharmaceutical Design Abeta Immunotherapy and Other Means to Remove Amyloid
Current Drug Targets - CNS & Neurological Disorders Evaluation and Management of Asymptomatic Bradyarrhythmias
Current Cardiology Reviews Short Term, Low Dose Simvastatin Pretreatment Alters Memory Immune Function Following Secondary Staphylococcus aureus Infection
Current Pharmaceutical Biotechnology Statins and Left Ventricular Function
Current Pharmaceutical Design Role of Subclinical Iatrogenic Hyperthyroidism in the Setting of Heart Disease and Arrhythmic Burden
Endocrine, Metabolic & Immune Disorders - Drug Targets Primary Antiphospholipid Syndrome and Pulmonary Hypertension
Current Pharmaceutical Design Functional Recovery After Stroke: A Review of Current Developments in Stroke Rehabilitation Research
Reviews on Recent Clinical Trials Cytoprotective and Antiproliferative Effects of HMG-CoA Reductase Inhibitors
Current Enzyme Inhibition Pleiotropic, Cardioprotective Effects of Omega-3 Polyunsaturated Fatty Acids
Mini-Reviews in Medicinal Chemistry